They use the Internet, the application of innovative technology and the assistance of licensed securities brokers when appropriate to provide a broad universe of accredited and institutional investors with efficient access to private company stock investment opportunities and to take friction out of the transaction process.
This morning, Roche announced that the Food and Drug Administration refused to consider the application for the TDM-1 breast cancer drug based on technology that it licensed from Immunogen, a Waltham, Mass. biotechnology company.